🧬 BioMed Pulse · 2026-09-26 02:01 UTC

BIOMED PULSE

Saturday, September 26, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in the Democratic Republic of the Congo is now the largest Ebola outbreak ever recorded in that country, with new provinces falling and case counts accelerating week over week. ^[1] Meanwhile, a CDC-expanded Listeria outbreak tied to prepared meals added 3 more illnesses and 1 additional death as of this morning — the second active food-safety emergency updated today. ^[2]

Overall mood: Alarming on outbreak fronts; cautiously active on longevity research and trials.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS (EBOLA) — DRC, NOW EXPANDING TO NEW PROVINCE

• As of September 25, 2026 the Bundibugyo virus disease outbreak in the DRC has spread to two additional health zones, including Bulu health zone in a newly affected province, Sud Ubangi, on the northwest border of the country. ^[1]
• Total affected health zones now stand at 63 across seven of the DRC's 26 provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, Tshopo, and now Sud Ubangi. ^[1]
• WHO's DON618 notes this is the largest Ebola outbreak ever reported in the DRC, expanding faster than any previous Ebola outbreak, and is characterized by sustained community transmission. ^[1]
• For context, as of July 17 the outbreak already had 2,124 confirmed cases and 828 deaths; the geographic spread has roughly doubled since that count. ^[3]
• CDC activated enhanced Ebola airport screening at Washington-Dulles and Atlanta earlier this year in response to the DRC/Uganda outbreak. ^{[4] [5]}
• The outbreak was first identified in Mongbwalu Health Zone, Ituri Province; Bundibugyo virus, a distinct Ebola species, was laboratory-confirmed by DRC's Institut national de recherche biomédicale (INRB) on May 14, 2026. ^[6]

LISTERIA — PREPARED MEALS, MULTISTATE USA

• CDC today expanded the ongoing Listeria monocytogenes outbreak to include additional prepared food products, reporting 3 new illnesses and 1 new death. ^{[2] [7]}
• CDC continues to urge consumers to check refrigerators and freezers for recalled prepared meals and discard them; new illnesses were still being reported despite earlier recalls. ^[8]

DRUG-RESISTANT BACTERIA — USA

• A CDC report published September 23, 2026 found a dramatic and sharp rise in a dangerous type of drug-resistant bacteria in the United States. ^[9]
• An extensively drug-resistant Salmonella strain linked to moringa powder capsules was previously documented, with three hospitalizations reported; the moringa-linked cluster has been expanding since at least late 2025. ^[10]

SYPHILIS IN NEWBORNS — USA

• New CDC data released September 24, 2026 show U.S. congenital syphilis cases increased for the 12th consecutive year in 2024, underscoring a persistent STI public health failure.

CANCER MORTALITY — USA

• The CDC Annual Report to the Nation (released September 22, 2026) shows falling overall U.S. cancer death rates, with progress against lung cancer cited as a primary driver.

ANIMAL RABIES — USA

• CDC issued a statement on September 10, 2026 noting increases in recent animal rabies activity and associated human exposures in the United States.

🧬 LONGEVITY & AGING

SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP) — SKIN CELLS

• Researchers published a method in Methods in Molecular Biology for characterizing the SASP — the inflammatory cocktail secreted by senescent cells — in both primary skin cells and iPSC-derived skin cells using multiplex assays.
• Understanding SASP in skin is relevant to both wound healing and age-related skin decline; authors include Koutsoukos, Kogut, and Bilousova.

RADIATION-INDUCED CELLULAR SENESCENCE — HAIR FOLLICLES

• A study in Genes and Disease found ionizing radiation causes dermal papilla cells (which anchor and nourish hair follicles) to senesce by inhibiting the FOXM1-KIF20A molecular pathway, potentially explaining radiation-linked hair loss and scalp aging.

MOLECULAR HYDROGEN AS ANTI-AGING TOOL

• A review in Medical Gas Research by Ichikawa, Sato, Takefuji, and Satoh (published September 12, 2026) describes molecular hydrogen as a potential guardian against environmental radiation damage, with implications for both radiation-exposed populations and general oxidative stress biology.

HIGH-DOSE INFLUENZA VACCINE AND FRAILTY — DANFLU-2 TRIAL ANALYSIS

• A prespecified analysis of the randomized DANFLU-2 trial published in Lancet Healthy Longevity found that high-dose influenza vaccine was more effective than standard-dose at preventing hospitalization specifically among frailer older adults — a clinically important "frailty-influenza paradox."
• An accompanying commentary by Verschoor and Kuchel in the same issue notes frail individuals face greater infection risk but may paradoxically derive greater vaccine benefit from high-dose formulations.

ANAESTHESIA FOR HIP FRACTURE IN OLDER PATIENTS

• A multicentre randomised clinical trial published in Lancet Healthy Longevity compared spinal versus general anaesthesia for hip fracture surgery in older patients in Germany and evaluated serious complications; results from Kowark et al. could influence perioperative care decisions for aging populations globally.

MRNA LIPID NANOPARTICLES FOR AGE-RELATED BONE REPAIR

• A study in Bioactive Materials by Cheng, Xi, Wang, and colleagues describes a dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol homeostasis to promote repair of age-related bone defects, pointing toward future gene-based treatments for osteoporosis-related fractures.

QUERCETIN-BASED HYDROGEL FOR OSTEOPOROTIC BONE

• Yin and colleagues in Bioactive Materials report a quercetin-derived carbon dot nanocomposite hydrogel incorporating M2 macrophage-derived migrasomes that responds to the bone microenvironment to promote regeneration of osteoporotic bone defects.

NARCICLASINE FOR ATHEROSCLEROSIS

• A single-cell sequencing-guided study in Genes and Disease identified narciclasine as a dual VCAM-1/ICAM-1 inhibitor — blocking two key molecular adhesion targets in atherosclerotic plaques — representing a novel pharmacological approach to cardiovascular aging.

NECROPTOSIS AND ENDOPLASMIC RETICULUM STRESS

• A Genes and Disease review by Li, Su, Tang, and colleagues links unfolded protein response (UPR) activity during ER stress to the regulation of necroptosis — a form of inflammatory cell death implicated in multiple age-related diseases including neurodegeneration and cardiovascular disease.

DEPRESCRIBING TRIALS — METHODOLOGICAL DEBATE

• Lancet Healthy Longevity published dueling commentaries by Hwang, Boockvar, and Steinman versus Van der Linden arguing that deprescribing clinical trials (reducing polypharmacy in older adults) must adopt a rationale-first framework before selecting trial design — a debate with real implications for aging populations on multiple medications.

💊 NEW CURES & APPROVALS

INLURIYO (IMLUNESTRANT TOSYLATE) — ELI LILLY AND CO

• Eli Lilly received a supplemental approval (SUPPL AP) for INLURIYO, containing imlunestrant tosylate, an oral selective estrogen receptor degrader (SERD) indicated in hormone receptor-positive breast cancer.

VERZENIO (ABEMACICLIB) — ELI LILLY AND CO

• Eli Lilly received a supplemental approval for VERZENIO (abemaciclib), a CDK4/6 inhibitor used in hormone receptor-positive, HER2-negative breast cancer, expanding its approved use.

NUBEQA (DAROLUTAMIDE) — BAYER HEALTHCARE

• Bayer Healthcare received a supplemental approval for NUBEQA (darolutamide), an androgen receptor inhibitor used in metastatic and non-metastatic castration-resistant prostate cancer.

SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — NOVARTIS

• Novartis received a supplemental approval for SCEMBLIX (asciminib hydrochloride), a STAMP inhibitor targeting the BCR-ABL1 myristoyl pocket used in chronic myeloid leukemia.

WINREVAIR (SOTATERCEPT-CSRK) — MERCK SHARP DOHME

• Merck received a supplemental approval for WINREVAIR (sotatercept-csrk), an activin signaling inhibitor for pulmonary arterial hypertension, extending its approved indications.

SOHONOS (PALOVAROTENE) — IPSEN

• Ipsen received a supplemental approval for SOHONOS (palovarotene), a retinoic acid receptor gamma agonist for fibrodysplasia ossificans progressiva (FOP), a rare and severe progressive ossification disorder.

AQNEURSA (LEVACETYLLEUCINE) — INTRABIO

• IntraBio received a supplemental approval for AQNEURSA (levacetylleucine) for Niemann-Pick disease type C, a rare lysosomal storage disorder with neurological deterioration.

DEFLAZACORT — HIKMA

• Hikma received an original ANDA approval for a generic formulation of deflazacort, a corticosteroid used in Duchenne muscular dystrophy.

LANREOTIDE ACETATE — AMNEAL

• Amneal received an original ANDA approval for a generic lanreotide acetate, a somatostatin analogue for acromegaly and certain neuroendocrine tumors.

ROCURONIUM BROMIDE — BAXTER HEALTHCARE CORP

• Baxter Healthcare received an original ANDA approval for rocuronium bromide, a neuromuscular blocking agent used in surgical anesthesia.

🧪 CLINICAL TRIALS

TRONTINEMAB — EARLY SYMPTOMATIC ALZHEIMER'S DISEASE

• A clinical trial registered on ClinicalTrials.gov (NCT07170150) is assessing the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease, targeting the range from mild cognitive impairment through mild dementia due to AD.

UROLITHIN A — GLUCOSE METABOLISM IN ADULTS 55 AND OLDER

• A randomized, triple-masked controlled trial (NCT06274749) is evaluating whether Urolithin A supplementation improves glucose metabolism in adults aged 55 and older, based on the hypothesis that aging impairs pancreatic insulin secretion and that UA may mitigate this decline.

PHYSICAL FRAILTY INTERVENTION — AEROBIC AND RESISTANCE TRAINING

• Trial NCT07513701 is assessing combined aerobic and resistance training to enhance physical reserve in physically frail older adults, with the aim of preserving both cognitive and physical function as primary outcomes.

VIRTUAL LIFE STORY CLUB — LONELINESS AND APATHY IN OLDER ADULTS

• Trial NCT06919094 is testing a virtual reminiscence therapy group (Life Story Club) to reduce loneliness and apathy in community-dwelling older adults, combining structured social engagement with personal narrative recall.

VELOCITY-LOSS TRAINING — PARKINSON'S DISEASE

• Trial NCT07840508 will compare resistance training at 10% versus 30% velocity-loss thresholds in older adults with Parkinson's disease, measuring muscle strength, power, and daily performance outcomes.

BPL-1357 BROAD INFLUENZA VACCINE — H1N1 CHALLENGE STUDY

• Trial NCT07215858 is testing BPL-1357, a candidate broad-spectrum influenza vaccine, against an H1N1 human challenge model, targeting pandemic preparedness needs beyond seasonal flu coverage.

PATIENT COACH SUPPORT — OLDER ADULTS WITH OBESITY

• Pilot trial NCT06624163 is evaluating whether adding a patient coach to a structured weight and lifestyle clinic program (OHWL Clinic) improves adherence outcomes in older adults with obesity.

BLEXIMENIB IN ACUTE MYELOID LEUKEMIA

• Trial NCT05453903 is a Phase 1/2 study determining the recommended Phase 2 dose of bleximenib in combination with AML-directed therapies, evaluating safety and tolerability in a dose-selection and expansion design.

📢 PUBLIC HEALTH

CDC AWARDS $176 MILLION FOR PUBLIC HEALTH INFRASTRUCTURE

• On September 25, 2026, CDC announced more than $176 million in funding to 48 public health partners to strengthen the U.S. public health system.

KINDERGARTEN VACCINATION RATES STABLE

• CDC data released August 17, 2026 show kindergarten vaccination rates remain high nationally, with only a 0.1% decline in coverage reported; officials noted stability despite ongoing anti-vaccine pressures.

CDC TRAVELER BIOSURVEILLANCE PASSES ONE MILLION PARTICIPANTS

• CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 30, 2026, enhancing capacity to detect novel pathogens at U.S. entry points.

U.S. COMPLETED WHO WITHDRAWAL

• The United States formally completed its withdrawal from the World Health Organization as of January 22, 2026, citing COVID-19 failures and politicization; WHO stated the withdrawal makes both the U.S. and the world less safe.

DRUG OVERDOSE DEATHS DECLINING

• Provisional 2024 CDC data show a 27% decrease in drug overdose deaths in the United States compared to prior peak years, continuing a trend first reported in early 2025.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified health professional for personal medical decisions.

📎 Sources

1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
2. CDC expands Listeria outbreak to include more prepared meals — CDC Newsroom
3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
4. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
5. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
7. Listeria Outbreak to include more Prepared Foods — CDC Newsroom
8. CDC continues to note illnesses despite product recalls and as… — CDC Newsroom
9. CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria — CDC Newsroom
10. Extensively drug-resistant <em>Salmonella</em> outbreak linked… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260926-02-v87 · 2026-09-26 02:01 UTC · pulse.uzylab.com